R Krishna

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi request reprint The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride
    Rajesh Krishna
    Aventis Drug Innovation and Approval, Bridgewater, NJ, USA
    Biopharm Drug Dispos 25:373-87. 2004
  2. ncbi request reprint Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs
    R Krishna
    Department of Advanced Therapeutics, British Columbia Cancer Agency, BC V5Z 4E6, Vancouver, Canada
    Eur J Pharm Sci 11:265-83. 2000
  3. ncbi request reprint In vitro protein binding studies with BMS-204352: lack of protein binding displacement interaction in human serum
    R Krishna
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08540, USA
    Biopharm Drug Dispos 22:41-4. 2001
  4. ncbi request reprint Disposition of radiolabeled BMS-204352 in rats and dogs
    Rajesh Krishna
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08540, USA
    Biopharm Drug Dispos 23:41-6. 2002
  5. ncbi request reprint Pharmacokinetics and dose proportionality of BMS-204352 after intravenous administration to dogs
    Rajesh Krishna
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543 4000, USA
    Biopharm Drug Dispos 23:83-6. 2002
  6. ncbi request reprint Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators
    R Krishna
    Department of Advanced Therapeutics, BC Cancer Agency, 600 West 10 th Ave, Vancouver, B C V5Z 4E6, Canada
    Curr Med Chem Anticancer Agents 1:163-74. 2001
  7. ncbi request reprint Pharmacokinetics and dose proportionality of BMS-204352 after intraarterial administration to rats
    Rajesh Krishna
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543 4000, USA
    Biopharm Drug Dispos 23:233-7. 2002
  8. ncbi request reprint Effect of dose and input rate on the brain penetration of BMS-204352 following intravenous administration to rats
    Rajesh Krishna
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543 4000, USA
    Biopharm Drug Dispos 23:227-31. 2002
  9. ncbi request reprint Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties
    R Krishna
    Department of Advanced Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Pharmacol Exp Ther 298:1206-12. 2001
  10. ncbi request reprint Visualization of bioavailable liposomal doxorubicin using a non-perturbing confocal imaging technique
    R Krishna
    Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, Canada
    Histol Histopathol 16:693-9. 2001

Collaborators

Detail Information

Publications17

  1. ncbi request reprint The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride
    Rajesh Krishna
    Aventis Drug Innovation and Approval, Bridgewater, NJ, USA
    Biopharm Drug Dispos 25:373-87. 2004
    ..5 kg and a 15 mg dose administered to children 6 months and older and weighing <or=10.5 kg produces exposures similar to those seen with the 60 mg dose in adults...
  2. ncbi request reprint Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs
    R Krishna
    Department of Advanced Therapeutics, British Columbia Cancer Agency, BC V5Z 4E6, Vancouver, Canada
    Eur J Pharm Sci 11:265-83. 2000
    ....
  3. ncbi request reprint In vitro protein binding studies with BMS-204352: lack of protein binding displacement interaction in human serum
    R Krishna
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08540, USA
    Biopharm Drug Dispos 22:41-4. 2001
    ..In conclusion, the potential for a drug-drug interaction due to alterations in protein binding with BMS-204352 is unlikely...
  4. ncbi request reprint Disposition of radiolabeled BMS-204352 in rats and dogs
    Rajesh Krishna
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08540, USA
    Biopharm Drug Dispos 23:41-6. 2002
    ..The absolute oral bioavailability was 55% in rats and 79% in dogs. Bioavailability and extent of absorption data suggest evidence of first pass metabolism of BMS-204352 in the rat and dog...
  5. ncbi request reprint Pharmacokinetics and dose proportionality of BMS-204352 after intravenous administration to dogs
    Rajesh Krishna
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543 4000, USA
    Biopharm Drug Dispos 23:83-6. 2002
    ..The high VSS value indicated that BMS-204352 was distributed extensively in the extravascular tissues. In conclusion, BMS-204352 exhibits linear pharmacokinetics over the dose range tested (0.4-2 mg/kg)...
  6. ncbi request reprint Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators
    R Krishna
    Department of Advanced Therapeutics, BC Cancer Agency, 600 West 10 th Ave, Vancouver, B C V5Z 4E6, Canada
    Curr Med Chem Anticancer Agents 1:163-74. 2001
    ....
  7. ncbi request reprint Pharmacokinetics and dose proportionality of BMS-204352 after intraarterial administration to rats
    Rajesh Krishna
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543 4000, USA
    Biopharm Drug Dispos 23:233-7. 2002
    ..54 to 2.08-4.70 h, respectively. In conclusion, BMS-204352 appears to exhibit dose-dependent pharmacokinetics in rats. In addition, there appeared to be some evidence of gender related differences in the pharmacokinetics of BMS-204352...
  8. ncbi request reprint Effect of dose and input rate on the brain penetration of BMS-204352 following intravenous administration to rats
    Rajesh Krishna
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543 4000, USA
    Biopharm Drug Dispos 23:227-31. 2002
    ..11) as compared to bolus (B/P of ca. 7-8) dose. The decline of BMS-204352 in the brain paralleled that of plasma independent of the input rate and dose...
  9. ncbi request reprint Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties
    R Krishna
    Department of Advanced Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Pharmacol Exp Ther 298:1206-12. 2001
    ..While the reduced systemic exposure to free vincristine correlates with reduced toxicity, additional information (such as liposome drug release properties) may be necessary to correlate pharmacokinetic behavior with antitumor activity...
  10. ncbi request reprint Visualization of bioavailable liposomal doxorubicin using a non-perturbing confocal imaging technique
    R Krishna
    Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, Canada
    Histol Histopathol 16:693-9. 2001
    ....
  11. ncbi request reprint Molecular and pharmacological strategies to overcome multidrug resistance
    J A Shabbits
    Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, BC, V5Z 4E6, Canada
    Expert Rev Anticancer Ther 1:585-94. 2001
    ..We also describe how liposomal drug delivery systems can be utilized to aid in achieving these goals...
  12. doi request reprint Studies on the pharmacokinetics and metabolism of a gamma-secretase inhibitor BMS-299897, and exploratory investigation of CYP enzyme induction
    M Zheng
    Metabolism and Pharmacokinetics, Bristol Myers Squibb Research and Development, Wallingford, CT, USA
    Xenobiotica 39:544-55. 2009
    ..A low potential for autoinduction in humans was predicted at a clinical dose of 250 mg and the prediction was consistent with the findings from a clinical multiple-dose study with BMS-299897 in probable Alzheimer's patients...
  13. ncbi request reprint Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled MaxiPost (BMS-204352) in humans
    Donglu Zhang
    Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ 08543 4000, USA
    Drug Metab Dispos 33:83-93. 2005
    ..Similar disposition, metabolism, pharmacokinetic, and protein covalent binding properties of (14)C-labeled BMS-204352 were observed in humans, dogs, and rats...
  14. ncbi request reprint Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
    Arthur Bergman
    Merck and Co Inc, Whitehouse Station, NJ 07065, USA
    Biopharm Drug Dispos 28:315-22. 2007
    ..80, 1.25). Additionally, the high-fat meal had no significant effect on T(max) or apparent terminal t(1/2). Thus, food does not affect the pharmacokinetics of sitagliptin and therefore can be administered without regard to food...
  15. ncbi request reprint Clearance and disposition of indometacin in chronically instrumented fetal lambs following a 3-day continuous intravenous infusion
    Rajesh Krishna
    Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada
    J Pharm Pharmacol 54:801-8. 2002
    ..CLpl of the drug is also low owing to the physicochemical properties of indometacin (high polarity) and the permeability characteristics of the sheep placenta...
  16. ncbi request reprint On the assessment of effects of food on the pharmacokinetics of drugs in early development
    Zhihong Li
    Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Biopharm Drug Dispos 23:165-71. 2002
    ..Perspectives on the value in predicting food-drug interactions during preclinical development, timing of clinical food-drug interaction studies, and implications of food effects are presented herein...
  17. ncbi request reprint Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
    Arthur Bergman
    Merck and Co Inc, Whitehouse Station, NJ 07065, USA
    Biopharm Drug Dispos 28:307-13. 2007
    ..5% pooled across doses) and renal clearance (344 ml/min pooled across doses) were not statistically significant. Sitagliptin was generally well tolerated at all the doses evaluated...